News Bidders lining up for Teva women's health unit Allergan generics buyout left Teva with $35m debts
News Roche's Herceptin facing further biosimilar threats in US Breast cancer blockbuster facing potential trio of US competitors.
News Teva's Cinqaero to challenge Nucala after clearing NICE Discount swings NICE decision, drug will compete with GSK rival
News EU authorities accuse Teva of breaking competition rules Teva accused of "pay for delay" deal with Cephalon.
News AZ CEO set to take charge at Teva - report Report raises concerns about outcome of MYSTIC trial.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
